Venous thromboembolism following major orthopedic surgery: Review of epidemiology and economics

Citation
J. Edelsberg et al., Venous thromboembolism following major orthopedic surgery: Review of epidemiology and economics, AM J HEAL S, 58(21), 2001, pp. S4-S13
Citations number
54
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
ISSN journal
10792082 → ACNP
Volume
58
Issue
21
Year of publication
2001
Supplement
2
Pages
S4 - S13
Database
ISI
SICI code
1079-2082(20011101)58:21<S4:VTFMOS>2.0.ZU;2-5
Abstract
The epidemiology and economics of venous thromboembolism (VTE) associated w ith hip and knee arthroplasty and surgical repair of hip fracture are revie wed. In the 1960s and 1970s, prior to the widespread use of prophylaxis, the ris k of VTE following major orthopedic surgery was substantial. The risk of fa tal pulmonary embolism (PE) following hip fracture repair may have been as high as 7.5%. With improvements in surgical and anesthetic techniques and t he use of anticoagulant prophylaxis, these risks have decreased significant ly for most patients. Current risks after hip and knee arthroplasty appear to be about 2.5% for deep vein thrombosis, 1% for nonfatal PE, and a few te nths of 1% for fatal PE over a three-month period following surgery. Becaus e of the traumatic nature of the injury, delays in getting to surgery, and their more advanced age and poorer overall health, hip fracture patients ap pear to have a greater risk of postoperative VTE, but data are lacking for a reliable estimate of current risk. The cost of VTE after major orthopedic surgery includes initial therapy (the chief component), followup care, and the expected costs of major hemorrhage (due to anticoagulation), recurrent VTE, and postthrombotic syndrome. The total cost per patient of such care is approximately $11,600. The risk of VTE after surgery to replace hip and knee joints and repair hip fracture is far lower today than in the 1960s and 1970s, but the cost of t reating VTE remains high: an estimated $11,600 per patient, including hospi talization costs.